person · Reporting owner
MCLAUGHLIN JOHN PETER
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LENSAR, Inc.LNSR · Entity 6733 | Director | May 25, 2023 | May 30, 2023 |
| PDL BIOPHARMA, INC.PDLI · Entity 143144 | Director | December 21, 2020 | December 23, 2020 |
| ROCKWELL MEDICAL, INC.RMTI · Entity 7426 | Director | June 17, 2021 | June 22, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LENSAR, Inc.
Report date May 25, 2023 · Filed May 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,631 |
Reported balance
After 2023-05-25 transaction · row 1
1 source rowRow 1 · 2023-05-25 · Grant · Acquired 9,288 · Balance 53,631 F1: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on May 25, 2024, subject to the Reporting Person's continued service to the Issuer through the vesting date. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.23 · Expires 2033-05-25 | Direct | 33,175 |
Reported balance
After 2023-05-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-25 · Grant · Acquired 33,175 · Balance 33,175 F2: The option vests in twelve (12) substantially equal monthly installments commencing June 25, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. The option was granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on May 25, 2024, subject to the Reporting Person's continued service to the Issuer through the vesting date. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer.
F2: The option vests in twelve (12) substantially equal monthly installments commencing June 25, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. The option was granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer.
PDL BIOPHARMA, INC.
Report date December 21, 2020 · Filed December 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 200,000 |
Ending reported balance
After 2020-12-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-12-21 · Sale · Disposed 50,000 · Balance 477,934 Row 2 · 2020-12-22 · Sale · Disposed 277,934 · Balance 200,000 |
ROCKWELL MEDICAL, INC.
Report date June 17, 2021 · Filed June 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 136,974 |
Reported balance
After 2021-06-17 transaction · row 1
1 source rowRow 1 · 2021-06-17 · Grant · Acquired 50,000 · Balance 136,974 F1: Restricted stock units vest on June 17, 2022, subject to the Reporting Person's continued service to the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.90 · Expires 2031-06-17 | Direct | 72,857 |
Reported balance
After 2021-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-17 · Grant · Acquired 72,857 · Balance 72,857 F2: Stock options shall vest in accordance with the following vesting schedule: (1) one-half (fifty percent) of the shares of Common Stock subject to this Option shall vest on June 17, 2023; and (2) the final one-half (remaining fifty percent) of the shares of Common Stock subject to this Option shall vest on June 17, 2025, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units vest on June 17, 2022, subject to the Reporting Person's continued service to the Issuer.
F2: Stock options shall vest in accordance with the following vesting schedule: (1) one-half (fifty percent) of the shares of Common Stock subject to this Option shall vest on June 17, 2023; and (2) the final one-half (remaining fifty percent) of the shares of Common Stock subject to this Option shall vest on June 17, 2025, subject to the Reporting Person's continued service to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2023 Filed May 30, 2023 17:04 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 33,175 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0000899243-23-014079 · doc4.xml · derivative · entry 2 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,175 Underlying: Common Stock · 33,175 shares Expires 2033-05-25 F2 · derivative.exercise_date: The option vests in twelve (12) substantially equal monthly installments commencing June 25, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. The option was granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| May 25, 2023 Filed May 30, 2023 17:04 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 9,288 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-014079 · doc4.xml · nonDerivative · entry 1 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,631 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on May 25, 2024, subject to the Reporting Person's continued service to the Issuer through the vesting date. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| May 25, 2022 Filed May 27, 2022 21:27 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 15,616 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020055 · doc4.xml · derivative · entry 2 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,616 Underlying: Common Stock · 15,616 shares Expires 2032-05-25 F3 · derivative.exercise_date: The option vests in twelve (12) substantially equal monthly installments commencing June 25, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. The option was granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| May 25, 2022 Filed May 27, 2022 21:27 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 4,285 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020055 · doc4.xml · nonDerivative · entry 1 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,343 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on May 25, 2023, subject to the Reporting Person's continued service to the Issuer through the vesting date. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer F2 · balance_after: Includes 40,058 shares of the Issuer's common stock received by the Reporting Person in connection with the October 1, 2020 spin-off (the "Spin-Off Date") of the Issuer from PDL BioPharma, Inc. ("PDL") on account of his ownership of shares of PDL common stock. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 21:25 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantStock Option (Right to Buy) · Derivative | 72,857 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001628280-21-012668 · wf-form4_162439706590346.xml · derivative · entry 2 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,857 Underlying: Common Stock · 72,857 shares Expires 2031-06-17 F2 · derivative.exercise_date: Stock options shall vest in accordance with the following vesting schedule: (1) one-half (fifty percent) of the shares of Common Stock subject to this Option shall vest on June 17, 2023; and (2) the final one-half (remaining fifty percent) of the shares of Common Stock subject to this Option shall vest on June 17, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 21:25 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-012668 · wf-form4_162439706590346.xml · nonDerivative · entry 1 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,974 F1 · kind: Restricted stock units vest on June 17, 2022, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 18, 2021 Filed May 20, 2021 16:15 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 20,847 | $0.00 Strike: $7.49 | $0.00 |
DisclosureSEC source: 0000899243-21-020137 · doc4.xml · derivative · entry 1 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,847 Underlying: Common Stock · 20,847 shares Expires 2031-05-18 F1 · derivative.exercise_date: The option vests in twelve (12) substantially equal monthly installments commencing June 18, 2021, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 16:07 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 13,445 | $0.00 Strike: $8.62 | $0.00 |
DisclosureSEC source: 0000899243-21-011932 · doc4.xml · derivative · entry 1 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,445 Underlying: Common Stock · 13,445 shares Expires 2031-03-12 F1 · derivative.exercise_date: The option vests as to one-third of the award on February 1, 2022 and, as to the remaining amount of the award, in twenty-four (24) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 16:10 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 28,249 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0000899243-21-004175 · doc4.xml · derivative · entry 1 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,249 Underlying: Common Stock · 28,249 shares Expires 2031-02-01 F1 · derivative.exercise_date: The option vests as to one-third of the award on February 1, 2022 and, as to the remaining amount of the award, in twenty-four (24) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 00:51 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | SaleCommon stock | 277,934 | $2.61 | $724,573.94 |
DisclosureSEC source: 0000882104-20-000213 · wf-form4_160868467873868.xml · nonDerivative · entry 2 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 00:51 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | SaleCommon stock | 50,000 | $2.62 | $131,200.00 |
DisclosureSEC source: 0000882104-20-000213 · wf-form4_160868467873868.xml · nonDerivative · entry 1 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477,934 Read SEC document |
| August 19, 2020 Filed Aug 24, 2020 10:06 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantStock Option (right to buy) · Derivative | 118,671 | $3.63 Strike: $3.63 | $430,775.73 |
DisclosureSEC source: 0000882104-20-000134 · wf-form4_159826349443710.xml · derivative · entry 2 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,671 Underlying: Common stock · 118,671 shares Expires 2030-08-19 F2 · derivative.exercise_date: The stock options will vest on the one year anniversary of the grant date, subject to acceleration of vesting upon a change in control or the Company filing a certificate of dissolution with the state of Delaware; provided that the recipient's continuous service has not terminated prior to such date. Read SEC document |
| August 19, 2020 Filed Aug 24, 2020 10:06 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantCommon stock | 25,826 | $0.00 | $0.00 |
DisclosureSEC source: 0000882104-20-000134 · wf-form4_159826349443710.xml · nonDerivative · entry 1 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 527,934 F1 · shares: The restricted stock will vest on the one year anniversary of the grant date, subject to acceleration of vesting upon a change in control or the Company filing a certificate of dissolution with the state of Delaware; provided that the recipient's continuous service has not terminated prior to such date. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:40 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantStock Option (Right to Buy) · Derivative | 34,024 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001628280-20-008126 · wf-form4_159000719341144.xml · derivative · entry 2 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,024 Underlying: Common Stock · 34,024 shares Expires 2030-05-18 F3 · derivative.exercise_date: Stock options vest on May 18, 2021, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:40 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 51,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-008126 · wf-form4_159000719341144.xml · nonDerivative · entry 1 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,974 F1 · kind: Restricted stock units vest on May 18, 2021, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 35,174 shares of common stock underlying unvested restricted stock units that vest based upon the achievement of certain time-based milestones. Subject to the Reporting Person's continued service to the Issuer, the 22,559 restricted stick units and 28,372 stock options granted to the Reporting Person on September 5, 2019 will vest on September 5, 2020, because the Issuer's Long Term Incentive Plan requires a minimum one-year vesting period for all awards. The Reporting Person's Form 4 filed on September 6, 2019 used a vesting date of June 6, 2019 in error. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:05 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 12,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-009242 · a4.xml · nonDerivative · entry 1 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,174 F1 · kind: Restricted stock units ("RSUs") issued for the Reporting Person's service as chairman of the Board of Directors of the Issuer. RSUs vest on January 29, 2021, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| September 05, 2019 Filed Sep 6, 2019 20:13 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantStock Option (Right to Buy) · Derivative | 28,372 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0001104659-19-049098 · a4.xml · derivative · entry 2 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,372 Underlying: Common Stock · 28,372 shares Expires 2029-09-05 F2 · derivative.exercise_date: Stock options vest on June 6, 2020, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| September 05, 2019 Filed Sep 6, 2019 20:13 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 22,559 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-049098 · a4.xml · nonDerivative · entry 1 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,559 F1 · kind: Restricted stock units vest on June 6, 2020, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 20, 2019 Filed Jul 8, 2019 21:02 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantStock Option (right to buy) · Derivative | 126,050 | $3.00 Strike: $3.00 | $378,150.00 |
DisclosureSEC source: 0000882104-19-000082 · wf-form4_156261974045691.xml · derivative · entry 1 MCLAUGHLIN JOHN PETER · CIK 0001277967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,050 Underlying: Common stock · 126,050 shares Expires 2029-06-19 F1 · derivative.exercise_date: The stock options shall vest on a monthly basis pro rata over the twelve (12) months following the grant date, provided that the recipient's continuous service has not terminated prior to the applicable vesting date. Read SEC document |
| December 31, 2018 Filed Jan 9, 2019 15:26 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | Disposition to issuerCommon stock | 123,449 | $0.00 | $0.00 |
DisclosureSEC source: 0000882104-19-000004 · wf-form4_154704756196374.xml · nonDerivative · entry 1 MCLAUGHLIN JOHN PETER · CIK 0001277967 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 502,108 F1 · shares: John McLaughlin retired from the Issuer as of December 31, 2018, and all unvested shares of restricted stock were forfeited back to the Issuer. Read SEC document |
| December 27, 2018 Filed Dec 28, 2018 23:28 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | Disposition to issuerCommon stock | 627,228 | $0.00 | $0.00 |
DisclosureSEC source: 0000882104-18-000128 · wf-form4_154603971973255.xml · nonDerivative · entry 1 MCLAUGHLIN JOHN PETER · CIK 0001277967 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,557 F1 · shares: Disposition of common stock due to performance criteria not being achieved under equity incentive plans. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 20:30 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantStock Option (right to buy) · Derivative | 1,922,100 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0000882104-18-000069 · wf-form4_152883543214291.xml · derivative · entry 1 MCLAUGHLIN JOHN PETER · CIK 0001277967 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,922,100 Underlying: Common stock · 1,922,100 shares Expires 2027-08-28 F1 · date: The stock options were approved by the compensation committee of the issuer's board of directors effective August 29, 2017, subject to stockholder approval of an amendment to the issuer's equity plan pursuant to which the stock option was granted. The issuer's stockholders approved the amendment on June 8, 2018. F2 · derivative.exercise_date: The stock options will vest as follows: (a) 25% of the shares subject to the option shall vest on August 28, 2018; (b) 25% of the shares subject to the option shall vest on a monthly basis pro rata over the thirty-six (36) months following August 28, 2018; (c) 25% of the shares subject to the option shall vest upon the price of the issuer's common stock closing above $3.91 for twenty (20) consecutive trading days; and (d) 25% of the shares subject to the option shall vest upon the price of the issuer's common stock closing above $4.41 for twenty (20) consecutive trading days, provided that the recipient's continuous service has not terminated prior to the applicable vesting date, subject to earlier vesting upon a change in control and certain qualifying terminations of employement provided in the severance agreement between the issuer and the recipient. Read SEC document |
| December 15, 2017 Filed Dec 20, 2017 01:04 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | Disposition to issuerCommon stock | 151,678 | $0.00 | $0.00 |
DisclosureSEC source: 0000882104-17-000128 · wf-form4_151373186919221.xml · nonDerivative · entry 1 MCLAUGHLIN JOHN PETER · CIK 0001277967 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,252,785 F1 · shares: Disposition of common stock due to performance criteria not being achieved under equity incentive plans. Read SEC document |
| March 04, 2017 Filed Mar 8, 2017 01:18 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantCommon stock | 588,235 | $2.04 | $1,199,999.40 |
DisclosureSEC source: 0000882104-17-000020 · wf-form4_148893589410926.xml · nonDerivative · entry 1 MCLAUGHLIN JOHN PETER · CIK 0001277967 · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,404,463 F1 · shares: The restricted stock will vest, provided that the officer remains employed by the Company and certain performance goals are achieved, based upon the following schedule: 50% on December 2018; 16.66% on December 2019; 16.66% on December 2020; and 16.66% on December 2021. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 21:15 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | Disposition to issuerCommon stock | 5,168 | $0.00 | $0.00 |
DisclosureSEC source: 0000882104-16-000247 · wf-form4_148183653568653.xml · nonDerivative · entry 1 MCLAUGHLIN JOHN PETER · CIK 0001277967 · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,228 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.